ProtoKinetix Receives Excellent Results from the University of British Columbia Eye Inflammation Study

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), is pleased to announce that it has received excellent results from the eye inflammation study conducted by UBC (University of British Columbia). The tests conducted by Dr. Gregory-Evans MD, PhD, FRCS, FRCOphth, were designed to determine whether the powerful anti-inflammatory AAGP™ molecule could be successfully delivered to inflamed areas throughout the eye. The result demonstrated that AAGP™ penetrates through the extremely protective barriers of the eye without side effects.

ProtoKinetix has proven the ability of AAGP™ to protect human cells against inflammation causing agents. There are many forms of eye inflammation that are typically treated with an aggressive course of corticosteroids. Due, in part, to the short effective life of topical steroids, current treatments involve the application on an hourly basis. These powerful drugs can lead to numerous sight threatening complications.

Dr. Gregory-Evans, a professor of Ophthalmology and Leadership Chair in Macular Research, concludes that AAGP™ penetrates the eye when topically applied as a twice a day or four times a day regimen. AAGP™ can be detected within the cornea and ciliary body. Drug was also seen to appear in retinal tissue, most convincingly when a four times a day regimen was used.

These results represent a major step in the development of a potent, non-steroidal, anti-inflammatory drug.

Ross L. Senior, President and CEO

Company Office:
ProtoKinetix Inc
Suite # 1500-2225 Folkestone Way
West Vancouver, BC
V7S 2Y6

Investor Contact:
604-926-6627
Email: info@protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.